Ocugen
- Company typePublic
- Founded2013
- HeadquartersMalvern, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Ocugen firmographics
Firmographics- Name
- Ocugen
- Legal name
- Ocugen, Inc.
- Website
- https://ocugen.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Ocugen industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Gene Therapies (HLAAACAG)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where Ocugen is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Ocugen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Gene Therapy Product Sales: Once approved, Ocugen plans to commercialize its gene therapy products directly in the US market. The company is building commercial capabilities including appointing a Chief Commercial Officer. Pricing is expected to be significantly below multi-million dollar typical gene therapy prices.
- Licensing Revenue: Ocugen receives upfront fees, development milestones, sales milestones, and royalties on net sales from regional licensing partners. Deals include Kwangdong Pharmaceutical (Korea) and Roots Pharmaceutical (MENA region).
- Collaboration Revenue: Ocugen reports modest collaboration income from partnerships, including revenue from NIAID/NIH for vaccine development programs.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Ocugen product offering
Product offeringCore offering
Ocugen develops a modifier gene therapy platform using AAV5 viral vectors to deliver nuclear hormone receptor genes (NR2E3, RORA) to retinal cells. The pipeline includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, designed as gene-agnostic, one-time subretinal injection treatments. The company also develops biologic (OCU200) and inhaled vaccine (OCU500/510/520) candidates.
Product overview
Ocugen is a patient-centric biotechnology company developing gene therapies, biologics, and vaccines. Its modifier gene therapy platform represents its core innovation, delivering breakthrough treatments for inherited retinal diseases. The gene therapy portfolio includes OCU400 (Phase 3 for retinitis pigmentosa), OCU410ST (Phase 2/3 for Stargardt disease), and OCU410 (Phase 2 for geographic atrophy). The biologics pipeline features OCU200 (Phase 1 for diabetic macular edema and wet AMD), while the vaccine pipeline includes OCU500 (COVID-19 inhaled vaccine), OCU510 (quadrivalent flu vaccine), and OCU520 (combination flu/COVID vaccine). The company operates from Malvern, PA, with partnerships including Bharat Biotech and CanSino Biologics.
Differentiator
Problem solved
Functional benefit
Products and services
- OCU400 (AAV-hNR2E3) A modifier gene therapy using AAV5 vector delivery of the NR2E3 nuclear hormone receptor gene for retinitis pigmentosa treatment. Designed as a gene-agnostic, one-time subretinal injection therapy targeting multiple genetic mutations causing RP.
- OCU410ST (AAV-hRORA) A modifier gene therapy using AAV5 vector delivery of the RORA gene for Stargardt disease, an orphan inherited retinal disease. Targets ABCA4 gene mutations causing photoreceptor degeneration.
- OCU410 (AAV-hRORA) A modifier gene therapy using AAV5 vector delivery of the RORA gene for geographic atrophy secondary to dry age-related macular degeneration. Targets lipid metabolism, oxidative stress, inflammation, and complement pathways.
- OCU200 (Transferrin-Tumstatin) A novel fusion protein biologic consisting of tumstatin and transferrin for treating diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. Uses integrin receptor targeting to regress abnormal blood vessels and inhibit neovascularization.
- OCU500 COVID-19 inhaled vaccine based on a chimpanzee adenovirus (ChAd) vector platform designed to reduce transmission with mucosal immunity through inhalation delivery.
- OCU510 Seasonal quadrivalent influenza inhaled vaccine using the ChAd platform designed to elicit both humoral (IgG) and mucosal (IgA) immune responses.
- OCU520 Combination quadrivalent seasonal influenza and COVID-19 inhaled vaccine using the ChAd platform for dual protection against both respiratory diseases.
Quantifiable outcome
- 31% reduction in geographic atrophy lesion growth at medium dose after 12 months (OCU410 Phase 2)
- +4 more outcomes
Companies that use Ocugen
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Ocugen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ocugen partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Roots Pharmaceutical and Al-Dhow International HoldingcoreBinding term sheet signed for exclusive license of OCU400 in retinitis pigmentosa across the MENA region, valued at up to $255 million in sales milestones plus a 22% royalty on net sales.
- Roots PharmaceuticalcoreBinding term sheet for exclusive license of OCU400 in retinitis pigmentosa covering the Middle East and North Africa region. Ocugen receives upfront fees and development milestones up to $4 million, sales milestone payments up to $255 million, and a 22% royalty on net sales, while manufacturing and supplying commercial product.
- Al-Dhow International HoldingcoreStrategic partner with Roots Pharmaceutical for exclusive license of OCU400 in retinitis pigmentosa across MENA region.
- Kwangdong PharmaceuticalcoreLicensing agreement granting exclusive Korean rights to OCU400 for retinitis pigmentosa. Ocugen receives upfront license fees and near-term development milestone payments up to $7.5 million, with potential sales milestones reaching $180 million or more and a 25% royalty on net sales over the first 10 years of commercialization.
- Carisma TherapeuticsminorOcugen's subsidiary OrthoCelix merged with Carisma Therapeutics in an all-stock reverse merger transaction, creating a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. Ocugen shareholders expected to own approximately 90% of combined entity.
- Bharat BiotechcoreBharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of vaccines and bio-therapeutics, and WHO Pre-qualifications. Located in Genome Valley in Hyderabad, India.
- CanSino BiologicscoreCanSino Biologics is an innovative biopharmaceutical company dedicated to vaccine development, manufacturing, and commercialization. Their commitment to quality and scientific expertise around clinical development and manufacturing has made them an important collaborator in Ocugen's modifier gene therapy program.
- NIH/NIAIDcoreOCU500 COVID-19 inhaled vaccine was selected by NIH/NIAID Project NextGen for inclusion in clinical trials. NIAID intends to initiate Phase 1 clinical trial for OCU500.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
Ocugen competitors and assessment
Company assessmentBroad incumbents
- Apellis Pharmaceuticals: Approved Syfovre for geographic atrophy (complement inhibitor), directly competing with Ocugen's OCU410. Larger, revenue-generating commercial-stage company in overlapping indication.
- Iveric Bio (Astellas): Approved Izervay for geographic atrophy, now part of Astellas. Represents major commercial-stage competitor to Ocugen's OCU410 in the GA indication with established market presence.
- uniQure: AAV-based gene therapy company with approved Hemgenix for hemophilia B and pipeline across multiple indications. Comparable as a gene therapy platform company with similar manufacturing and regulatory challenges to Ocugen.
- Spark Therapeutics (Roche): Pioneer in ophthalmology gene therapy (approved Luxturna for RPE65-mediated retinal dystrophy); now part of Roche. Sets commercial benchmark for retinal gene therapy pricing and access, and competes with Ocugen's OCU400 in adjacent RP patient populations.
Emerging players
- Editas Medicine: Clinical-stage genome editing company with ophthalmology programs (EDIT-101 for LCA10) targeting inherited retinal diseases. Represents an alternative technology approach (CRISPR vs. AAV gene replacement) competing for similar patient populations.
Direct peers
- REGENXBIO: AAV gene therapy developer with multiple ophthalmology programs (RGX-314 for wet AMD) and proprietary NAV technology platform. Closely comparable to Ocugen given shared AAV-based approach to retinal diseases and similar pipeline stage profile.
- MeiraGTx: Clinical-stage gene therapy company with leading ophthalmology programs (AAV-RPGR for RP, AAV-CNGB3 and AAV-CNGA3 for achromatopsia). Directly competes with Ocugen in inherited retinal disease space with similar modality.
- GenSight Biologics: Clinical-stage gene therapy company targeting retinal diseases (Lumevoq for Leber hereditary optic neuropathy, GS030 for RP). Similar platform technology and ophthalmology focus to Ocugen, with comparable stage and European market orientation.
- Adverum Biotechnologies: Clinical-stage gene therapy company focused on ocular diseases (wet AMD, diabetic macular edema) using AAV vectors. Directly comparable to Ocugen given overlapping retinal indications and AAV platform approach.
- Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek for dystrophic epidermolysis bullosa) using HSV-based delivery platform with similar patient-centric rare disease commercial model. Comparable in size, stage, and gene therapy commercialization approach to Ocugen.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ocugen social profiles
Digital presenceOcugen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ocugen leadership team
Management profileNumber of profiles
Profiles13 records
Ocugen subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ocugen funding detail
Funding detailFunding overview
Funding rounds11 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ocugen M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ocugen
What does Ocugen do?
Ocugen develops a modifier gene therapy platform using AAV5 viral vectors to deliver nuclear hormone receptor genes (NR2E3, RORA) to retinal cells. The pipeline includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, designed as gene-agnostic, one-time subretinal injection treatments. The company also develops biologic (OCU200) and inhaled vaccine (OCU500/510/520) candidates.
Is Ocugen a public or private company?
Ocugen is a public company. It is classified as public and is currently operating.
When was Ocugen founded?
Ocugen was founded in 2013. It employs 51 to 100 people.
Where is Ocugen based?
Ocugen is headquartered in Malvern, United States, in the North America region.
How does Ocugen make money?
Three revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are licensing Revenue and collaboration Revenue.
Who are Ocugen's main competitors?
Broad incumbents on record are Apellis Pharmaceuticals, Iveric Bio (Astellas), uniQure and Spark Therapeutics (Roche). Editas Medicine is listed as an emerging player. Direct peers are REGENXBIO, MeiraGTx, GenSight Biologics, Adverum Biotechnologies and Krystal Biotech.
Does Ocugen have an API?
No public API is recorded for Ocugen.
What industry is Ocugen in?
Ocugen's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.